Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction

Irene A Retmana; Jing Wang; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen; Rolf W Sparidans

doi:10.1016/j.jchromb.2017.07.034

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction

Irene A Retmana
, Jing Wang
, Alfred H Schinkel
, Jan H M Schellens
, Jos H Beijnen
, Rolf W Sparidans

Netherlands Cancer Institute

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

A bioanalytical assay for quizartinib -a potent, and selective FLT3 tyrosine kinase inhibitor- in mouse plasma was developed and validated. Salting-out assisted liquid-liquid extraction (SALLE), using acetonitrile and magnesium sulfate, was selected as sample pretreatment with deuterated quizartinib as internal standard. Separation was performed with reversed-phase liquid chromatography followed by detection with positive electrospray-triple quadrupole mass spectrometry in the selected reaction monitoring mode. The assay was successfully validated for mouse plasma in a 2-2000ng/ml calibration range with r(2)=0.9958±0.0028 (n=7) for linear regression with the inverse square of the concentration as a weighting factor. The within-run precision (n=18), between-run precision and accuracy were 2.9-6.0%, 4.5-8.9% and 91.7-109.4% respectively. The drug was stable under all relevant conditions. Finally, the assay was successfully applied in a pharmacokinetic pilot study in plasma of FVB/NRj mice treated with quizartinb orally.

Original language	English
Pages (from-to)	300-305
Number of pages	6
Journal	Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume	1061-1062
DOIs	https://doi.org/10.1016/j.jchromb.2017.07.034
Publication status	Published - 1 Sept 2017

Keywords

Animals
Benzothiazoles
Chromatography, Liquid
Female
Linear Models
Mice
Phenylurea Compounds
Protein Kinase Inhibitors
Reproducibility of Results
Tandem Mass Spectrometry

Access to Document

10.1016/j.jchromb.2017.07.034

LiquidFinal published version, 343 KBLicence: Taverne

Cite this

Retmana, I. A., Wang, J., Schinkel, A. H., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2017). Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1061-1062, 300-305. https://doi.org/10.1016/j.jchromb.2017.07.034

Retmana, Irene A ; Wang, Jing ; Schinkel, Alfred H et al. / Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2017 ; Vol. 1061-1062. pp. 300-305.

@article{3da82f923e8a432eaa1a485b8779fb00,

title = "Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction",

abstract = "A bioanalytical assay for quizartinib -a potent, and selective FLT3 tyrosine kinase inhibitor- in mouse plasma was developed and validated. Salting-out assisted liquid-liquid extraction (SALLE), using acetonitrile and magnesium sulfate, was selected as sample pretreatment with deuterated quizartinib as internal standard. Separation was performed with reversed-phase liquid chromatography followed by detection with positive electrospray-triple quadrupole mass spectrometry in the selected reaction monitoring mode. The assay was successfully validated for mouse plasma in a 2-2000ng/ml calibration range with r(2)=0.9958±0.0028 (n=7) for linear regression with the inverse square of the concentration as a weighting factor. The within-run precision (n=18), between-run precision and accuracy were 2.9-6.0\%, 4.5-8.9\% and 91.7-109.4\% respectively. The drug was stable under all relevant conditions. Finally, the assay was successfully applied in a pharmacokinetic pilot study in plasma of FVB/NRj mice treated with quizartinb orally.",

keywords = "Animals, Benzothiazoles, Chromatography, Liquid, Female, Linear Models, Mice, Phenylurea Compounds, Protein Kinase Inhibitors, Reproducibility of Results, Tandem Mass Spectrometry",

author = "Retmana, \{Irene A\} and Jing Wang and Schinkel, \{Alfred H\} and Schellens, \{Jan H M\} and Beijnen, \{Jos H\} and Sparidans, \{Rolf W\}",

year = "2017",

month = sep,

day = "1",

doi = "10.1016/j.jchromb.2017.07.034",

language = "English",

volume = "1061-1062",

pages = "300--305",

journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",

issn = "1570-0232",

publisher = "Elsevier BV",

}

Retmana, IA, Wang, J, Schinkel, AH, Schellens, JHM, Beijnen, JH & Sparidans, RW 2017, 'Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1061-1062, pp. 300-305. https://doi.org/10.1016/j.jchromb.2017.07.034

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. / Retmana, Irene A; Wang, Jing; Schinkel, Alfred H et al.
In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1061-1062, 01.09.2017, p. 300-305.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction

AU - Retmana, Irene A

AU - Wang, Jing

AU - Schinkel, Alfred H

AU - Schellens, Jan H M

AU - Beijnen, Jos H

AU - Sparidans, Rolf W

PY - 2017/9/1

Y1 - 2017/9/1

N2 - A bioanalytical assay for quizartinib -a potent, and selective FLT3 tyrosine kinase inhibitor- in mouse plasma was developed and validated. Salting-out assisted liquid-liquid extraction (SALLE), using acetonitrile and magnesium sulfate, was selected as sample pretreatment with deuterated quizartinib as internal standard. Separation was performed with reversed-phase liquid chromatography followed by detection with positive electrospray-triple quadrupole mass spectrometry in the selected reaction monitoring mode. The assay was successfully validated for mouse plasma in a 2-2000ng/ml calibration range with r(2)=0.9958±0.0028 (n=7) for linear regression with the inverse square of the concentration as a weighting factor. The within-run precision (n=18), between-run precision and accuracy were 2.9-6.0%, 4.5-8.9% and 91.7-109.4% respectively. The drug was stable under all relevant conditions. Finally, the assay was successfully applied in a pharmacokinetic pilot study in plasma of FVB/NRj mice treated with quizartinb orally.

AB - A bioanalytical assay for quizartinib -a potent, and selective FLT3 tyrosine kinase inhibitor- in mouse plasma was developed and validated. Salting-out assisted liquid-liquid extraction (SALLE), using acetonitrile and magnesium sulfate, was selected as sample pretreatment with deuterated quizartinib as internal standard. Separation was performed with reversed-phase liquid chromatography followed by detection with positive electrospray-triple quadrupole mass spectrometry in the selected reaction monitoring mode. The assay was successfully validated for mouse plasma in a 2-2000ng/ml calibration range with r(2)=0.9958±0.0028 (n=7) for linear regression with the inverse square of the concentration as a weighting factor. The within-run precision (n=18), between-run precision and accuracy were 2.9-6.0%, 4.5-8.9% and 91.7-109.4% respectively. The drug was stable under all relevant conditions. Finally, the assay was successfully applied in a pharmacokinetic pilot study in plasma of FVB/NRj mice treated with quizartinb orally.

KW - Animals

KW - Benzothiazoles

KW - Chromatography, Liquid

KW - Female

KW - Linear Models

KW - Mice

KW - Phenylurea Compounds

KW - Protein Kinase Inhibitors

KW - Reproducibility of Results

KW - Tandem Mass Spectrometry

U2 - 10.1016/j.jchromb.2017.07.034

DO - 10.1016/j.jchromb.2017.07.034

M3 - Article

C2 - 28772226

SN - 1570-0232

VL - 1061-1062

SP - 300

EP - 305

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

ER -

Retmana IA, Wang J, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2017 Sept 1;1061-1062:300-305. doi: 10.1016/j.jchromb.2017.07.034

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction

Abstract

Keywords

Access to Document

Fingerprint

Cite this